ASCO 2010 CN Homepage

News
Article

ASCO: Annual Meeting '10 Our on-site coverage of the American Society of Clinical Oncology's annual meeting: Five internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting…

ASCO: Annual Meeting '10
Our on-site coverage of the American Society of Clinical Oncology's annual meeting: Five internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting…

Gastrointestinal Cancers
GI cancer experts Richard M. Goldberg, MD, and Peter C. Enzinger, MD: Clinical investigators share their insight into the best GI sessions and practice-changing trends.

Renal Cell Carcinoma
Andrew J. Armstrong, MD, MSc, and Robert J. Motzer, MD: Learn about the paradigm-shifting advent of targeted therapies; find out what’s down the pike in RCC.

Hematologic Cancers
Samuel M. Silver, MD, PhD: an internationally recognized hematologist shares insight into the future of blood cancer treatment and research, selecting the most relevant content for ASCO 2010.

Plus the hottest American Society of Clinical Oncology news on Breast Cancer, from the CancerNetwork's reporters!

2010 Focus on Breast Cancer

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content